New drug ibrutinib shows promise for Hard-to-Treat blood cancers
NCT ID NCT01589302
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to see how many patients are alive and cancer-free at two years. The study also tracks overall response rates and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ibrutinib
- What this could lead to
- If successful, this could show that ibrutinib helps control advanced CLL, SLL, or B-PLL for at least two years in patients who have not responded to prior treatments.
- What could go wrong
- This is a single-institution Phase 2 trial, not a large randomized study. Results may not apply to all patients, and side effects like bleeding, infection, or heart rhythm issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New transplant recipe aims to tame Graft-Versus-Host disease
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- Engineered immune cells take on tough blood cancers in early trial
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack